CD8A and non-Hodgkin lymphoma: This may include CD8+ T cell infiltration and recruitment of innate immune cells as it was previously reported in preclinical studies that used radioconjugates to enhance the response to ICIs in mouse models of melanoma [19, 46], non-Hodgkin lymphoma [47], and colon cancer [18].